Monogenic mouse models of social dysfunction: Implications for autism

Behavioural Brain Research

Volumn 251, Issue , 2013, Pages 75-84

  Oddi, D ^a,b   Crusio, W E ^c,d   D'Amato, F R ^a,b   Pietropaolo, S ^c,d  

^a CNR   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d UMR 5287   (France)

Author keywords

Fmr1; Fragile X syndrome; Mouse models; Mu receptor; Opioid system; Social behaviors; Ultrasonic communication

Indexed keywords

ARGIPRESSIN; DELTA OPIATE RECEPTOR; ENDORPHIN; G PROTEIN COUPLED RECEPTOR; METHYL CPG BINDING PROTEIN 2; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; NOCICEPTIN RECEPTOR; OXYTOCIN; OXYTOCIN RECEPTOR;

ARTICLE; AUTISM; DOSE RESPONSE; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; FMR1 GENE; FRAGILE X SYNDROME; GENE; GENE DISRUPTION; GENE INACTIVATION; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC VARIABILITY; HUMAN; LOW DRUG DOSE; MECP2 GENE; MONOGENIC DISORDER; NONHUMAN; OPRD1 GENE; OPRK1 GENE; OPRM1 GENE; PHENOTYPE; PRIORITY JOURNAL; SOCIAL DISABILITY;

FMR1; FRAGILE X SYNDROME; MOUSE MODELS; MU RECEPTOR; OPIOID SYSTEM; SOCIAL BEHAVIORS; ULTRASONIC COMMUNICATION;

ANIMALS; AUTISTIC DISORDER; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; MICE; SOCIAL BEHAVIOR;

EID: 84880331524     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.01.002     Document Type: Article

References (169)

1. Fombonne E. The prevalence of autism. Journal of American Medical Association 2003, 289(1):87-89.
2. Rutter M. Incidence of autism spectrum disorders: changes over time and their meaning. Acta Paediatrica 2005, 94(1):2-15.
3. Autism and developmental disabilities monitoring network surveillance year 2008 principal investigators, prevalence of autism spectrum disorders - autism and developmental disabilities monitoring network, 14 sites, United States, 2008 2012, Centers for Disease Control and Prevention (CDD), Atlanta, GA, p. 1-19.
4. American psychiatric association. Diagnostic and statistical manual of mental disorders (DSM-IV). Washington, DC; 1994.
5. American psychiatric association. Diagnostic and statistical manual of mental disorders (DSM-V). Washington, DC; 2000.
6. Kolevzon A., Gross R., Reichenberg A. Prenatal and perinatal risk factors for autism: a review and integration of findings. Archives of Pediatrics and Adolescent Medicine 2007, 161(4):326-333.
7. Miyake K., Hirasawa T., Koide T., Kubota T. Epigenetics in autism and other neurodevelopmental diseases. Advances in Experimental Medicine and Biology 2012, 724:91-98.
8. Ronald A., Hoekstra R.A. Autism spectrum disorders and autistic traits: a decade of new twin studies. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2011, 156B(3):255-274.
9. Betancur C. Etiological heterogeneity in autism spectrum disorders: more than 100 genetic and genomic disorders and still counting. Brain Research 2011, 1380:42-77.
10. Geschwind D.H. Genetics of autism spectrum disorders. Trends in Cognitive Sciences 2011, 15(9):409-416.
11. De Rubeis S., Bagni C. Regulation of molecular pathways in the Fragile X syndrome: insights into Autism Spectrum Disorders. Journal of Neurodevelopmental Disorders 2011, 3(3):257-269.
12. DiCicco-Bloom E., Lord C., Zwaigenbaum L., Courchesne E., Dager S.R., Schmitz C., et al. The developmental neurobiology of autism spectrum disorder. Journal of Neuroscience 2006, 26(26):6897-6906.
13. Summers K.M. Relationship between genotype and phenotype in monogenic diseases: relevance to polygenic diseases. Human Mutation 1996, 7(4):283-293.
14. Llaneza D.C., DeLuke S.V., Batista M., Crawley J.N., Christodulu K.V., Frye C.A. Communication, interventions, and scientific advances in autism: a commentary. Physiology and Behavior 2010, 100(3):268-276.
15. McFarlane H.G., Kusek G.K., Yang M., Phoenix J.L., Bolivar V.J., Crawley J.N. Autism-like behavioral phenotypes in BTBR T+tf/J mice. Genes, Brain and Behavior 2008, 7(2):152-163.
16. Moy S.S., Nadler J.J., Magnuson T.R., Crawley J.N. Mouse models of autism spectrum disorders: the challenge for behavioral genetics. American Journal of Medical Genetics Part C: Seminars in Medical Genetics 2006, 142C(1):40-51.
17. Scattoni M.L., Ricceri L., Crawley J.N. Unusual repertoire of vocalizations in adult BTBR T+tf/J mice during three types of social encounters. Genes, Brain and Behavior 2011, 10(1):44-56.
18. Crawley J.N. Mouse behavioral assays relevant to the symptoms of autism. Brain Pathology 2007, 17(4):448-459.
19. Crawley J.N. Designing mouse behavioral tasks relevant to autistic-like behaviors. Mental Retardation and Developmental Disabilities Research Reviews 2004, 10(4):248-258.
20. Moy S.S., Nadler J.J., Poe M.D., Nonneman R.J., Young N.B., Koller B.H., et al. Development of a mouse test for repetitive, restricted behaviors: relevance to autism. Behavioural Brain Research 2008, 188(1):178-194.
21. Silverman J.L., Yang M., Lord C., Crawley J.N. Behavioural phenotyping assays for mouse models of autism. Nature Reviews Neuroscience 2010, 11(7):490-502.
22. Kanner L. Autistic disturbances of affective contact. Nervous Child 1943, 2:217-250.
23. Rutter M. Concepts of autism: a review of research. Journal of Child Psychology and Psychiatry and Allied Disciplines 1968, 9(1):1-25.
24. American psychiatric association. Diagnostic and statistical manual of mental disorders (DSM-III). Washington, DC; 1980.
25. American psychiatric association. Diagnostic and statistical manual of mental disorders (DSM-III-R). Washington, DC; 1987.
26. Happe F., Ronald A., Plomin R. Time to give up on a single explanation for autism. Nature Neuroscience 2006, 9(10):1218-1220.
27. Baranek G.T. Efficacy of sensory and motor interventions for children with autism. Journal of Autism and Developmental Disorders 2002, 32(5):397-422.
28. McAlonan G.M., Daly E., Kumari V., Critchley H.D., van Amelsvoort T., Suckling J., et al. Brain anatomy and sensorimotor gating in Asperger's syndrome. Brain 2002, 125(Pt 7):1594-1606.
29. Perry W., Minassian A., Lopez B., Maron L., Lincoln A. Sensorimotor gating deficits in adults with autism. Biological Psychiatry 2007, 61(4):482-486.
30. Yuhas J., Cordeiro L., Tassone F., Ballinger E., Schneider A., Long J.M., et al. Brief report sensorimotor gating in idiopathic autism and autism associated with Fragile X syndrome. Journal of Autism and Developmental Disorders 2011, 41(2):248-253.
31. Ornitz E.M., Lane S.J., Sugiyama T., de Traversay J. Startle modulation studies in autism. Journal of Autism and Developmental Disorders 1993, 23(4):619-637.
32. Polimeni M.A., Richdale A.L., Francis A.J. A survey of sleep problems in autism, Asperger's disorder and typically developing children. Journal of Intellectual Disability Research 2005, 49(Pt 4):260-268.
33. Gail Williams P., Sears L.L., Allard A. Sleep problems in children with autism. Journal of Sleep Research 2004, 13(3):265-268.
34. Muris P., Steerneman P., Merckelbach H., Holdrinet I., Meesters C. Comorbid anxiety symptoms in children with pervasive developmental disorders. Journal of Anxiety Disorders 1998, 12(4):387-393.
35. Pearson D.A., Loveland K.A., Lachar D., Lane D.M., Reddoch S.L., Mansour R., et al. A comparison of behavioral and emotional functioning in children and adolescents with Autistic Disorder and PDD-NOS. Child Neuropsychology 2006, 12(4-5):321-333.
36. Tuchman R., Rapin I. Epilepsy in autism. Lancet Neurology 2002, 1(6):352-358.
37. Constantino J.N., Gruber C.P., Davis S., Hayes S., Passanante N., Przybeck T. The factor structure of autistic traits. Journal of Child Psychology and Psychiatry and Allied Disciplines 2004, 45(4):719-726.
38. Frazier T.W., Youngstrom E.A., Kubu C.S., Sinclair L., Rezai A. Exploratory and confirmatory factor analysis of the autism diagnostic interview-revised. Journal of Autism and Developmental Disorders 2008, 38(3):474-480.
39. Szatmari P., Merette C., Bryson S.E., Thivierge J., Roy M.A., Cayer M., et al. Quantifying dimensions in autism: a factor-analytic study. Journal of the American Academy of Child and Adolescent Psychiatry 2002, 41(4):467-474.
40. Radde R., Duma C., Goedert M., Jucker M. The value of incomplete mouse models of Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging 2008, 35(Suppl. 1):S70-S74.
41. Ricceri L., Moles A., Crawley J. Behavioral phenotyping of mouse models of neurodevelopmental disorders: relevant social behavior patterns across the life span. Behavioural Brain Research 2007, 176(1):40-52.
42. Nadler J.J., Moy S.S., Dold G., Trang D., Simmons N., Perez A., et al. Automated apparatus for quantitation of social approach behaviors in mice. Genes, Brain and Behavior 2004, 3(5):303-314.
43. Branchi I., Santucci D., Alleva E. Ultrasonic vocalisation emitted by infant rodents: a tool for assessment of neurobehavioural development. Behavioural Brain Research 2001, 125(1-2):49-56.
44. D'Amato F.R., Scalera E., Sarli C., Moles A. Pups call, mothers rush: does maternal responsiveness affect the amount of ultrasonic vocalizations in mouse pups?. Behavior Genetics 2005, 35(1):103-112.
45. Hennessy M.B., Miller E.E., Shair H.N. Brief exposure to the biological mother "potentiates" the isolation behavior of precocial Guinea pig pups. Developmental Psychobiology 2006, 48(8):653-659.
46. Shair H.N. Acquisition and expression of a socially mediated separation response. Behavioural Brain Research 2007, 182(2):180-192.
47. Scattoni M.L., Crawley J., Ricceri L. Ultrasonic vocalizations: a tool for behavioural phenotyping of mouse models of neurodevelopmental disorders. Neuroscience and Biobehavioral Reviews 2009, 33(4):508-515.
48. Holy T.E., Guo Z. Ultrasonic songs of male mice. PLoS Biology 2005, 3(12):e386.
49. Moles A., Costantini F., Garbugino L., Zanettini C., D'Amato F.R. Ultrasonic vocalizations emitted during dyadic interactions in female mice: a possible index of sociability?. Behavioural Brain Research 2007, 182(2):223-230.
50. Persico A.M., Bourgeron T. Searching for ways out of the autism maze: genetic, epigenetic and environmental clues. Trends in Neurosciences 2006, 29(7):349-358.
51. Buxbaum J.D., Betancur C., Bozdagi O., Dorr N.P., Elder G.A., Hof P.R. Optimizing the phenotyping of rodent ASD models: enrichment analysis of mouse and human neurobiological phenotypes associated with high-risk autism genes identifies morphological, electrophysiological, neurological, and behavioral features. Molecular Autism 2012, 3(1):1.
52. Geschwind D.H. Autism: many genes, common pathways?. Cell 2008, 135(3):391-395.
53. Ey E., Leblond C.S., Bourgeron T. Behavioral profiles of mouse models for autism spectrum disorders. Autism Research 2011, 4(1):5-16.
54. Takayanagi Y., Yoshida M., Bielsky I.F., Ross H.E., Kawamata M., Onaka T., et al. Pervasive social deficits: but normal parturition, in oxytocin receptor-deficient mice. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(44):16096-16101.
55. Winslow J.T., Hearn E.F., Ferguson J., Young L.J., Matzuk M.M., Insel T.R. Infant vocalization: adult aggression, and fear behavior of an oxytocin null mutant mouse. Hormones and Behavior 2000, 37(2):145-155.
56. Feldman R. Oxytocin and social affiliation in humans. Hormones and Behavior 2012, 61(3):380-391.
57. Hammock E.A., Young L.J. Oxytocin, vasopressin and pair bonding: implications for autism. Philosophical Transactions of the Royal Society of London, Series B: Biological Sciences 2006, 361(1476):2187-2198.
58. Modi M.E., Young L.J. The oxytocin system in drug discovery for autism: animal models and novel therapeutic strategies. Hormones and Behavior 2012, 61(3):340-350.
59. Ferguson J.N., Young L.J., Hearn E.F., Matzuk M.M., Insel T.R., Winslow J.T. Social amnesia in mice lacking the oxytocin gene. Nature Genetics 2000, 25(3):284-288.
60. Winslow J.T., Insel T.R. The social deficits of the oxytocin knockout mouse. Neuropeptides 2002, 36(2-3):221-229.
61. Caldwell H.K. Neurobiology of sociability. Advances in Experimental Medicine and Biology 2012, 739:187-205.
62. Stevenson E.L., Caldwell H.K. The vasopressin 1b receptor and the neural regulation of social behavior. Hormones and Behavior 2012, 61(3):277-282.
63. Scattoni M.L., McFarlane H.G., Zhodzishsky V., Caldwell H.K., Young W.S., Ricceri L., et al. Reduced ultrasonic vocalizations in vasopressin 1b knockout mice. Behavioural Brain Research 2008, 187(2):371-378.
64. Bielsky I.F., Hu S.B., Ren X., Terwilliger E.F., Young L.J. The V1a vasopressin receptor is necessary and sufficient for normal social recognition: a gene replacement study. Neuron 2005, 47(4):503-513.
65. Bielsky I.F., Hu S.B., Szegda K.L., Westphal H., Young L.J. Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice. Neuropsychopharmacology 2004, 29(3):483-493.
66. Bielsky I.F., Hu S.B., Young L.J. Sexual dimorphism in the vasopressin system: lack of an altered behavioral phenotype in female V1a receptor knockout mice. Behavioural Brain Research 2005, 164(1):132-136.
67. Chen R.Z., Akbarian S., Tudor M., Jaenisch R. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nature Genetics 2001, 27(3):327-331.
68. Shahbazian M., Young J., Yuva-Paylor L., Spencer C., Antalffy B., Noebels J., et al. Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron 2002, 35(2):243-254.
69. Picker J.D., Yang R., Ricceri L., Berger-Sweeney J. An altered neonatal behavioral phenotype in Mecp2 mutant mice. Neuroreport 2006, 17(5):541-544.
70. Moretti P., Bouwknecht J.A., Teague R., Paylor R., Zoghbi H.Y. Abnormalities of social interactions and home-cage behavior in a mouse model of Rett syndrome. Human Molecular Genetics 2005, 14(2):205-220.
71. Splawski I., Timothy K.W., Sharpe L.M., Decher N., Kumar P., Bloise R., et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 2004, 119(1):19-31.
72. Bader P.L., Faizi M., Kim L.H., Owen S.F., Tadross M.R., Alfa R.W., et al. Mouse model of Timothy syndrome recapitulates triad of autistic traits. Proceedings of the National Academy of Sciences of the United States of America 2011, 108(37):15432-15437.
73. Evans C.J., Keith D.E., Jr H., Magendzo K., Edwards R.H. Cloning of a delta opioid receptor by functional expression. Science 1992, 258(5090):1952-1955.
74. Kieffer B.L. Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides. Cellular and Molecular Neurobiology 1995, 15(6):615-635.
75. Kieffer B.L., Befort K., Gaveriaux-Ruff C., Hirth C.G. The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proceedings of the National Academy of Sciences of the United States of America 1992, 89(24):12048-12052.
76. Darland T., Heinricher M.M., Grandy D.K. Orphanin FQ/nociceptin: a role in pain and analgesia, but so much more. Trends in Neurosciences 1998, 21(5):215-221.
77. Le Merrer J., Becker J.A.J., Befort K., Kieffer B.L. Reward processing by the opioid system in the brain. Physiological Reviews 2009, 89(4):1379-1412.
78. Cooper Z.D., Shi Y.-G., Woods J.H. Reinforcer-dependent enhancement of operant responding in opioid-withdrawn rats. Psychopharmacology 2010, 212(3):369-378.
79. van Ree J.M., Gerrits M.A., Vanderschuren L.J. Opioids, reward and addiction: an encounter of biology, psychology, and medicine. Pharmacological Reviews 1999, 51(2):341-396.
80. Berrendero F., Kieffer B.L., Maldonado R. Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in mu-opioid receptor knock-out mice. The Journal of Neuroscience 2002, 22(24):10935-10940.
81. Contet C., Kieffer B.L., Befort K. Mu opioid receptor: a gateway to drug addiction. Current Opinion in Neurobiology 2004, 14(3):370-378.
82. Depue R.A., Morrone-Strupinsky J.V. A neurobehavioral model of affiliative bonding: implications for conceptualizing a human trait of affiliation. The Behavioral and Brain Sciences 2005, 28(3):313-350.
83. Nelson E.E., Panksepp J. Brain substrates of infant-mother attachment: contributions of opioids, oxytocin, and norepinephrine. Neuroscience and Biobehavioral Reviews 1998, 22(3):437-452.
84. Piepponen T.P., Kivastik T., Katajamäki J., Zharkovsky A., Ahtee L. Involvement of opioid mu 1 receptors in morphine-induced conditioned place preference in rats. Pharmacology, Biochemistry, and Behavior 1997, 58(1):275-279.
85. Blass E.M., Fitzgerald E. Milk-induced analgesia and comforting in 10-day-old rats: opioid mediation. Pharmacology, Biochemistry, and Behavior 1998, 29(1):9-13.
86. Carden S.E., Hofer M.A. Isolation-induced vocalization in Wistar rat pups is not increased by naltrexone. Physiology & Behavior 1991, 49(6):1279-1282.
87. Winslow J.T., Insel T.R. Endogenous opioids: do they modulate the rat pup's response to social isolation?. Behavioral Neuroscience 1991, 105(2):253-263.
88. Najam N., Panksepp J. Effect of chronic neonatal morphine and naloxone on sensorimotor and social development of young rats. Pharmacology, Biochemistry, and Behavior 1989, 33(3):539-544.
89. Beatty W.W., Costello K.B. Naloxone and play fighting in juvenile rats. Pharmacology, Biochemistry, and Behavior 1982, 17(5):905-907.
90. Panksepp J., Jalowiec J., DeEskinazi F.G., Bishop P. Opiates and play dominance in juvenile rats. Behavioral Neuroscience 1985, 99(3):441-453.
91. Siegel M.A., Jensen R.A., Panksepp J. The prolonged effects of naloxone on play behavior and feeding in the rat. Behavioral and Neural Biology 1985, 44(3):509-514.
92. Trezza V., Vanderschuren L.J.M.J. Cannabinoid and opioid modulation of social play behavior in adolescent rats: differential behavioral mechanisms. European Neuropsychopharmacology 2008, 18(7):519-530.
93. Trezza V., Damsteegt R., Achterberg E.J.M., Vanderschuren L.J.M.J. Nucleus accumbens μ-opioid receptors mediate social reward. The Journal of Neuroscience 2011, 31(17):6362-6370.
94. Sinchak K., Micevych P.E. Progesterone blockade of estrogen activation of mu-opioid receptors regulates reproductive behavior. The Journal of Neuroscience 2001, 21(15):5723-5729.
95. Panksepp J., Herman B.H., Vilberg T., Bishop P., DeEskinazi F.G. Endogenous opioids and social behavior. Neuroscience and Biobehavioral Reviews 1980, 4(4):473-487.
96. Burkett J.P., Spiegel L.L., Inoue K., Murphy A.Z., Young L.J. Activation of μ-opioid receptors in the dorsal striatum is necessary for adult social attachment in monogamous prairie voles. Neuropsychopharmacology 2011, 36(11):2200-2210.
97. Bouvard M.P., Leboyer M., Launay J.M., Recasens C., Plumet M.H., Waller-Perotte D., et al. Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study. Psychiatry Research 1995, 58(3):191-201.
98. Panksepp J., Lensing P., Leboyer M., Bouvard M.P., Naltrexone Other potential new pharmacological treatments of autism. Brain Dysfunction 1991, 4:281-300.
99. Barr C.S., Schwandt M.L., Lindell S.G., Higley J.D., Maestripieri D., Goldman D., et al. Variation at the mu-opioid receptor gene (OPRM1) influences attachment behavior in infant primates. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(13):5277-5281.
100. Copeland W.E., Sun H., Costello E.J., Angold A., Heilig M.A., Barr C.S. Child μ-opioid receptor gene variant influences parent-child relations. Neuropsychopharmacology 2011, 36(6):1165-1170.
101. Way B.M., Taylor S.E., Eisenberger N.I. Variation in the mu-opioid receptor gene (OPRM1) is associated with dispositional and neural sensitivity to social rejection. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(35):15079-15084.
102. Kieffer B.L., Gavériaux-Ruff C. Exploring the opioid system by gene knockout. Progress in Neurobiology 2002, 66(5):285-306.
103. Sora I., Elmer G., Funada M., Pieper J., Li X.F., Hall F.S., et al. Mu opiate receptor gene dose effects on different morphine actions: evidence for differential in vivo mu receptor reserve. Neuropsychopharmacology 2001, 25(1):41-54.
104. Matthes H.W., Smadja C., Valverde O., Vonesch J.L., Foutz A.S., Boudinot E., et al. Activity of the delta-opioid receptor is partially reduced, whereas activity of the kappa-receptor is maintained in mice lacking the mu-receptor. The Journal of Neuroscience 1998, 18(18):7285-7295.
105. Monory K., Bourin M.C., Spetea M., Tömböly C., Tóth G., Matthes H.W., et al. Specific activation of the mu opioid receptor (MOR) by endomorphin 1 and endomorphin 2. The European Journal of Neuroscience 2000, 12(2):577-584.
106. Becker A., Grecksch G., Brodemann R., Kraus J., Peters B., Schroeder H., et al. Morphine self-administration in mu-opioid receptor-deficient mice. Naunyn-Schmiedebergs Archives of Pharmacology 2000, 361(6):584-589.
107. Sora I., Takahashi N., Funada M., Ujike H., Revay R.S., Donovan D.M., et al. Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proceedings of the National Academy of Sciences of the United States of America 1997, 94(4):1544-1549.
108. Tian M., Broxmeyer H.E., Fan Y., Lai Z., Zhang S., Aronica S., et al. Altered hematopoiesis: behavior, and sexual function in mu opioid receptor-deficient mice. Journal of Experimental Medicine 1997, 185(8):1517-1522.
109. Hosohata Y., Vanderah T.W., Burkey T.H., Ossipov M.H., Kovelowski C.J., Sora I., et al. delta-Opioid receptor agonists produce antinociception and [35S]GTPgammaS binding in mu receptor knockout mice. European Journal of Pharmacology 2000, 388(3):241-248.
110. Qiu C., Sora I., Ren K., Uhl G., Dubner R. Enhanced delta-opioid receptor-mediated antinociception in mu-opioid receptor-deficient mice. European Journal of Pharmacology 2000, 387(2):163-169.
111. Filliol D., Ghozland S., Chluba J., Martin M., Matthes H.W., Simonin F., et al. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nature Genetics 2000, 25(2):195-200.
112. Olmstead M.C., Ouagazzal A.M., Kieffer B.L. Mu and delta opioid receptors oppositely regulate motor impulsivity in the signaled nose poke task. PLoS One 2009, 4(2):e4410.
113. Jamot L., Matthes H.W., Simonin F., Kieffer B.L., Roder J.C. Differential involvement of the mu and kappa opioid receptors in spatial learning. Genes, Brain and Behavior 2003, 2(2):80-92.
114. Jang C.G., Lee S.Y., Yoo J.H., Yan J.J., Song D.K., Loh H.H., et al. Impaired water maze learning performance in mu-opioid receptor knockout mice. Brain Research. Molecular Brain Research 2003, 117(1):68-72.
115. Sanders M.J., Kieffer B.L., Fanselow M.S. Deletion of the mu opioid receptor results in impaired acquisition of Pavlovian context fear. Neurobiology of Learning and Memory 2005, 84(1):33-41.
116. Wohr M., Moles A., Schwarting R.K., D'Amato F.R. Lack of social exploratory activation in male mu-opioid receptor KO mice in response to playback of female ultrasonic vocalizations. Society for Neuroscience 2011, 6(1):76-87.
117. Papaleo F., Kieffer B.L., Tabarin A., Contarino A. Decreased motivation to eat in mu-opioid receptor-deficient mice. European Journal of Neuroscience 2007, 25(11):3398-3405.
118. Moles A., Kieffer B.L., D'Amato F.R. Deficit in attachment behavior in mice lacking the mu-opioid receptor gene. Science 2004, 304(5679):1983-1986.
119. Lahvis G.P., Alleva E., Scattoni M.L. Translating mouse vocalizations: prosody and frequency modulation. Genes, Brain and Behavior 2011, 10(1):4-16.
120. Portfors C.V. Types and functions of ultrasonic vocalizations in laboratory rats and mice. Journal of the American Association for Laboratory Animal Science 2007, 46(1):28-34.
121. Esposito G., Venuti P. Understanding early communication signals in autism: a study of the perception of infants' cry. Journal of Intellectual Disability Research 2010, 54(3):216-223.
122. Cinque C., Pondiki S., Oddi D., Di Certo M.G., Marinelli S., Troisi A., et al. Modeling socially anhedonic syndromes: genetic and pharmacological manipulation of opioid neurotransmission in mice. Translational Psychiatry 2012, 3:e155.
123. Crawford D.C., Acuna J.M., Sherman S.L. FMR1 and the Fragile X syndrome: human genome epidemiology review. Genetics in Medicine 2001, 3(5):359-371.
124. Verkerk A.J., Pieretti M., Sutcliffe J.S., Fu Y.H., Kuhl D.P., Pizzuti A., et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in Fragile X syndrome. Cell 1991, 65(5):905-914.
125. Fu Y.H., Kuhl D.P., Pizzuti A., Pieretti M., Sutcliffe J.S., Richards S., et al. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 1991, 67(6):1047-1058.
126. Pieretti M., Zhang F.P., Fu Y.H., Warren S.T., Oostra B.A., Caskey C.T., et al. Absence of expression of the FMR-1 gene in Fragile X syndrome. Cell 1991, 66(4):817-822.
127. Greenough W.T., Klintsova A.Y., Irwin S.A., Galvez R., Bates K.E., Weiler I.J. Synaptic regulation of protein synthesis and the fragile X protein. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(13):7101-7106.
128. Loesch D.Z., Bui Q.M., Grigsby J., Butler E., Epstein J., Huggins R.M., et al. Effect of the fragile X status categories and the fragile X mental retardation protein levels on executive functioning in males and females with fragile X. Neuropsychology 2003, 17(4):646-657.
129. Loesch D.Z., Hay D.A. Clinical features and reproductive patterns in fragile X female heterozygotes. Journal of Medical Genetics 1988, 25(6):407-414.
130. Hagerman R.J., Amiri K., Cronister A. Fragile X checklist. American Journal of Medical Genetics 1991, 38(2-3):283-287.
131. Hatton D.D., Sideris J., Skinner M., Mankowski J., Bailey D.B., Roberts J., et al. Autistic behavior in children with Fragile X syndrome: prevalence, stability, and the impact of FMRP. American Journal of Medical Genetics Part A 2006, 140A(17):1804-1813.
132. Rogers S.J., Wehner D.E., Hagerman R. The behavioral phenotype in fragile X: symptoms of autism in very young children with Fragile X syndrome, idiopathic autism, and other developmental disorders. Journal of Developmental and Behavioral Pediatrics 2001, 22(6):409-417.
133. Bailey D.B., Hatton D.D., Skinner M., Mesibov G. Autistic behavior: FMR1 protein, and developmental trajectories in young males with Fragile X syndrome. Journal of Autism and Developmental Disorders 2001, 31(2):165-174.
134. Bailey D.B., Mesibov G.B., Hatton D.D., Clark R.D., Roberts J.E., Mayhew L. Autistic behavior in young boys with Fragile X syndrome. Journal of Autism and Developmental Disorders 1998, 28(6):499-508.
135. Brock M., Hatton D. Distinguishing features of autism in boys with Fragile X syndrome. Journal of Intellectual Disability Research 2010, 54(10):894-905.
136. Symons F.J., Clark R.D., Hatton D.D., Skinner M., Bailey D.B. Self-injurious behavior in young boys with Fragile X syndrome. American Journal of Medical Genetics Part A 2003, 118A(2):115-121.
137. Loesch D.Z., Bui Q.M., Dissanayake C., Clifford S., Gould E., Bulhak-Paterson D., et al. Molecular and cognitive predictors of the continuum of autistic behaviours in fragile X. Neuroscience and Biobehavioral Reviews 2007, 31(3):315-326.
138. Dutch-Belgian Fragile X Consortium Fmr1 knockout mice: a model to study fragile X mental retardation. Cell 1994, 78(1):23-33.
139. Bernardet M., Crusio W.E. Fmr1 KO mice as a possible model of autistic features. The Scientific World Journal 2006, 6:1164-1176.
140. Bardoni B., Davidovic L., Bensaid M., Khandjian E.W. The Fragile X syndrome: exploring its molecular basis and seeking a treatment. Expert Reviews in Molecular Medicine 2006, 8(8):1-16.
141. Hoogeveen A.T., Willemsen R., Oostra B.A. Fragile X syndrome: the Fragile X related proteins, and animal models. Microscopy Research and Technique 2002, 57(3):148-155.
142. Heulens I., Kooy F. Fragile X syndrome: from gene discovery to therapy. Frontiers in Bioscience 2011, 16:1211-1232.
143. Liu Z.H., Chuang D.M., Smith C.B. Lithium ameliorates phenotypic deficits in a mouse model of Fragile X syndrome. International Journal of Neuropsychopharmacology 2011, 1-13.
144. Mines M.A., Yuskaitis C.J., King M.K., Beurel E., Jope R.S. GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of Fragile X syndrome and autism. PLoS One 2010, 5(3):e9706.
145. Mineur Y.S., Huynh L.X., Crusio W.E. Social behavior deficits in the Fmr1 mutant mouse. Behavioural Brain Research 2006, 168(1):172-175.
146. D'Hooge R., Nagels G., Franck F., Bakker C.E., Reyniers E., Storm K., et al. Mildly impaired water maze performance in male Fmr1 knockout mice. Neuroscience 1997, 76(2):367-376.
147. Paradee W., Melikian H.E., Rasmussen D.L., Kenneson A., Conn P.J., Warren S.T. Fragile X mouse: strain effects of knockout phenotype and evidence suggesting deficient amygdala function. Neuroscience 1999, 94(1):185-192.
148. The Dutch-Belgian Fragile X Consortium Fmr1 knockout mice: a model to study fragile X mental retardation. Cell 1994, 78(1):23-33.
149. Van Dam D., D'Hooge R., Hauben E., Reyniers E., Gantois I., Bakker C.E., et al. Spatial learning, contextual fear conditioning and conditioned emotional response in Fmr1 knockout mice. Behavioural Brain Research 2000, 117(1-2):127-136.
150. Yan Q.J., Asafo-Adjei P.K., Arnold H.M., Brown R.E., Bauchwitz R.P. A phenotypic and molecular characterization of the fmr1-tm1Cgr fragile X mouse. Genes, Brain and Behavior 2004, 3(6):337-359.
151. Pietropaolo S., Guilleminot A., Martin B., D'Amato F.R., Crusio W.E. Genetic-background modulation of core and variable autistic-like symptoms in Fmr1 knock-out mice. PLoS One 2011, 6(2):e17073.
152. Rotschafer S.E., Trujillo M.S., Dansie L.E., Ethell I.M., Razak K.A. Minocycline treatment reverses ultrasonic vocalization production deficit in a mouse model of Fragile X syndrome. Brain Research 2011, 1439:7-14.
153. Spencer C.M., Alekseyenko O., Hamilton S.M., Thomas A.M., Serysheva E., Yuva-Paylor L.A., et al. Modifying behavioral phenotypes in Fmr1KO mice: genetic background differences reveal autistic-like responses. Autism Research 2011, 4(1):40-56.
154. Dobkin C., Rabe A., Dumas R., El Idrissi A., Haubenstock H., Brown W.T. Fmr1 knockout mouse has a distinctive strain-specific learning impairment. Neuroscience 2000, 100(2):423-429.
155. Roy S., Watkins N., Heck D. Comprehensive analysis of ultrasonic vocalizations in a mouse model of Fragile X syndrome reveals limited, call type specific deficits. PLoS One 2012, 7(9):e44816.
156. Markham J.A., Beckel-Mitchener A.C., Estrada C.M., Greenough W.T. Corticosterone response to acute stress in a mouse model of Fragile X syndrome. Psychoneuroendocrinology 2006, 31(6):781-785.
157. Baker K.B., Wray S.P., Ritter R., Mason S., Lanthorn T.H., Savelieva K.V. Male and female Fmr1 knockout mice on C57 albino background exhibit spatial learning and memory impairments. Genes, Brain and Behavior 2010, 9(6):562-574.
158. Hall F.S., Sora I., Uhl G.R. Ethanol consumption and reward are decreased in mu-opiate receptor knockout mice. Psychopharmacology 2001, 154(1):43-49.
159. Job M.O., Tang A., Hall F.S., Sora I., Uhl G.R., Bergeson S.E., et al. Mu (mu) opioid receptor regulation of ethanol-induced dopamine response in the ventral striatum: evidence of genotype specific sexual dimorphic epistasis. Biological Psychiatry 2007, 62(6):627-634.
160. Egashira N., Tanoue A., Matsuda T., Koushi E., Harada S., Takano Y., et al. Impaired social interaction and reduced anxiety-related behavior in vasopressin V1a receptor knockout mice. Behavioural Brain Research 2007, 178(1):123-127.
161. Wang H., Liang S., Burgdorf J., Wess J., Yeomans J. Ultrasonic vocalizations induced by sex and amphetamine in M2, M4, M5 muscarinic and D2 dopamine receptor knockout mice. PLoS One 2008, 3(4):e1893.
162. Kaffman A., Krystal J.H. New frontiers in animal research of psychiatric illness. Methods in Molecular Biology 2012, 829:3-30.
163. Dawson G., Burner K. Behavioral interventions in children and adolescents with autism spectrum disorder: a review of recent findings. Current Opinion in Pediatrics 2011, 23(6):616-620.
164. LeBlanc L.A., Gillis J.M. Behavioral interventions for children with autism spectrum disorders. Pediatric Clinics of North America 2012, 59(1):147-164. xi-xii.
165. Ospina M.B., Krebs Seida J., Clark B., Karkhaneh M., Hartling L., Tjosvold L., et al. Behavioural and developmental interventions for autism spectrum disorder: a clinical systematic review. PLoS One 2008, 3(11):e3755.
166. Bilousova T.V., Dansie L., Ngo M., Aye J., Charles J.R., Ethell D.W., et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. Journal of Medical Genetics 2009, 46(2):94-102.
167. Dolen G., Carpenter R.L., Ocain T.D., Bear M.F. Mechanism-based approaches to treating fragile X. Pharmacology & Therapeutics 2010, 127(1):78-93.
168. Meredith R.M., Holmgren C.D., Weidum M., Burnashev N., Mansvelder H.D. Increased threshold for spike-timing-dependent plasticity is caused by unreliable calcium signaling in mice lacking fragile X gene FMR1. Neuron 2007, 54(4):627-638.
169. Restivo L., Ferrari F., Passino E., Sgobio C., Bock J., Oostra B.A., et al. Enriched environment promotes behavioral and morphological recovery in a mouse model for the Fragile X syndrome. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(32):11557-11562.